NICE TAs

03/06/2026

TA1161: Sotatercept for treating pulmonary arterial hypertension

03/06/2026

TA1159: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment

03/06/2026

TA1160: Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

29/05/2026

TA1158: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

29/05/2026

TA1157: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over

21/05/2026

TA1156: Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

20/05/2026

TA1155: Rozanolixizumab for treating antibody-positive generalised myasthenia gravis

07/05/2026

TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

07/05/2026

TA1154: Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

07/05/2026

TA1153: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

06/05/2026

TA1151: Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)

30/04/2026

TA1149: Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma

29/04/2026

TA1148: Sodium zirconium cyclosilicate for treating hyperkalaemia (review of TA599)

29/04/2026

TA1147: vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

28/04/2026

TA1146: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

21/04/2026

TA1145: Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

08/04/2026

TA1144: Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)

31/03/2026

TA1143: Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

26/03/2026

TA1142: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

17/03/2026

TA1141: Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)